Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery

Inclusion Criteria: * ≥40 and ≤80 years old. * Patients with hypertension (systolic blood pressure \[BP\] \>155 mm Hg) and/or requiring 2 or more antihypertensive medications: no restrictions will be placed on antihypertensive agents, although loop diuretics will be temporarily changed to diluting site agents (eg, hydrochlorothiazide, indapamide, metolazone) prior to each blood oxygen level-dependent magnetic resonance imaging (BOLD-MRI) study performed during the trial, unless, in the judgment of the Investigator, the change represents a hazard to the patient. ARAS patients will be identified based upon radiologic and clinical criteria suggestive of renovascular hypertension and/or hemodynamically significant renovascular disease \>60% lumen occlusion (determined by quantitative computed tomography angiography or Doppler ultrasound velocity \>200 cm/sec). * Have an estimated glomerular filtration rate of ≥15 ml/min/1.73 m2 calculated using the Modification of Diet in Renal Disease (MDRD) formula. * Have no contraindications to angiography such as severe contrast allergy. * Have no contraindications to non-contrast magnetic resonance evaluations such as a pacemaker or magnetically active metal fragments. * Able to comply with protocol. * Women of childbearing age must: * Have a negative pregnancy serum human chorionic gonadotropin test prior to receiving study drug. * Agree to use two forms of contraception for 3 months following receipt of the study drug. * Men who are sexu…